49840-90-6

Usage

Uses

Used in Pharmaceutical Industry:
6-methylpyridazine-3-carbonitrile is used as a synthetic intermediate for the development of a range of pharmaceutical products. Its unique structure allows for the creation of diverse drug molecules, contributing to advancements in medicinal chemistry.
Used in Agricultural Industry:
In the agricultural sector, 6-methylpyridazine-3-carbonitrile serves as a key component in the production of pesticides and herbicides. Its incorporation enhances the effectiveness of these agrochemicals, promoting more efficient and targeted crop protection.
Used in Organic Chemistry:
6-methylpyridazine-3-carbonitrile also finds application in the field of organic chemistry as a building block for synthesizing complex organic compounds. Its reactivity and structural features facilitate the construction of intricate molecular architectures, expanding the scope of organic synthesis.
Due to its multifaceted utility and the ongoing research into its properties, 6-methylpyridazine-3-carbonitrile continues to be a compound of interest across different scientific and industrial domains.

Upstream product

• 106861-15-8 2-(4-toluenesulfonyl)-2,3-dihydro-6-methyl-3-pyridazinecarbonitrile 
• 1632-76-4 3-methylpyridazine 
• 7677-24-9 trimethylsilyl cyanide 
• 6674-22-2 1,8-diazabicyclo[5.4.0]undec-7-ene 
• 98-59-9 p-toluenesulfonyl chloride 
• 557-21-1 zinc(II) cyanide 
• 1121-79-5 3-chloro-6-methylpyridazine 

Downstream Products

• 64210-60-2 6-methyl-3-pyridazinecarboxylic acid 

Relevant academic research and scientific papers

C?H Cyanation of 6-Ring N-Containing Heteroaromatics

Heteroaromatic nitriles are important compounds in drug discovery, both for their prevalence in the clinic and due to the diverse range of transformations they can undergo. As such, efficient and reliable methods to access them have the potential for far-reaching impact across synthetic chemistry and the biomedical sciences. Herein, we report an approach to heteroaromatic C?H cyanation through triflic anhydride activation, nucleophilic addition of cyanide, followed by elimination of trifluoromethanesulfinate to regenerate the cyanated heteroaromatic ring. This one-pot protocol is simple to perform, is applicable to a broad range of decorated 6-ring N-containing heterocycles, and has been shown to be suitable for late-stage functionalization of complex drug-like architectures.

3-(6-ALKOXY-5-CHLOROBENZO[D]ISOXAZOL-3-YL)PROPANOIC ACID USEFUL AS KYNURENINE MONOOXYGENASE INHIBITORS

Compound of formula (I) wherein R1 is heteroaryl either unsubstituted or substituted by methyl, ethyl, halo or =O; and R2 is H, methyl or ethyl; and salts thereof are KMO inhibitors and may be useful in the treatment of various disor

1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES

The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.

SUBSTITUTED PYRIDIZINONE DERIVATIVES AS PDE10 INHIBITORS

The present invention is directed to substituted pyridizinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

SUBSTITUTED PYRIDIZINONE DERIVATIVES AS PDE10 INHIBITORS

The present invention is directed to substituted pyridizinone compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

ANTITHROMBOTIC AGENTS

This invention relates to thrombin inhibiting compounds having the Formula IX--Y--NH--(CH 2) r--G I where X, Y, r and G have the values defined in the description, as well as pharmaceutical formulations containing those compounds and methods of their use as thrombin inhibitors, coagulation inhibitors, and thromboembolic disorder agents.

ANTITHROMBOTIC AGENTS

This invention relates to thrombin inhibiting compounds having the FormulaIX--Y--NH--(CH 2) r--G I where X, Y, r and G have the values defined in the description, as well as pharmaceutical formulations containing those compounds and methods of their use as thrombin inhibitors, coagulation inhibitors, and thromboembolic disorder agents.

ANTITHROMBOTIC AGENTS

This invention relates to thrombin inhibiting compounds having the FormulaIX--Y--NH--(CH 2) r--G I where X, Y, r and G have the values defined in the description, as well as pharmaceutical formulations containing those compounds and methods of their use as thrombin inhibitors, coagulation inhibitors, and thromboembolic disorder agents.

ANTITHROMBOTIC AGENTS

This invention relates to thrombin inhibiting compounds having the FormulaIX--Y--NH--(CH 2) r--G I where X, Y, r and G have the values defined in the description, as well as pharmaceutical formulations containing those compounds and methods of their use as thrombin inhibitors, coagulation inhibitors, and thromboembolic disorder agents.

ANTITHROMBOTIC AGENTS

This invention relates to thrombin inhibiting compounds having the FormulaIX--Y--NH--(CH 2) r--G I where X, Y, r and G have the values defined in the description, as well as pharmaceutical formulations containing those compounds and methods of their use as thrombin inhibitors, coagulation inhibitors, and thromboembolic disorder agents.